Announcements Trials
Browse Landscape

Phase

Phase 2 4Phase 3 3Phase 1/2 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Thoracic 1

Conditions

Carcinoma, Non-Small-Cell Lung 1

Interventions

Cyclophosphamide 143pembrolizumab 127Nivolumab 116Carboplatin 99Dexamethasone 93Rituximab 91Paclitaxel 87Gemcitabine 85Lenalidomide 75Cytarabine 74Radiotherapy 73Cisplatin 70Bevacizumab 64Etoposide 62fludarabine phosphate 58fludarabine 56Ipilimumab 55Docetaxel 54Bortezomib 54Prednisone 49Doxorubicin 48Temozolomide 47Everolimus 46Erlotinib Hydrochloride 46Fluorouracil 44Azacitidine 44Capecitabine 43Calcium Dobesilate 43Filgrastim 42Melphalan 41

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 1/2 × Has results × Single Person × Clear all
NCT00960115 2015-10-21

Study of Tecemotide (L-BLP25) in Participants With Stage III Unresectable Non-small Cell Lung Cancer (NSCLC) Following Primary Chemoradiotherapy

Merck KGaA, Darmstadt, Germany

Phase 1/2 Completed
178 enrolled 11 charts
Thoracic

Carcinoma, Non-Small-Cell Lung

Data powered by HemOnc (CC BY 4.0) Colophon âš¡